Aptar Pharma will launch eDose Counter for MDIs Integrating a Proprietary Sensing Technology at CPHI/ICSE Europe Barcelona 2016.
Aptar Pharma eDose Counter for metered dose inhalers (MDIs)
Aptar Pharma will unveil its eDose Counter for metered dose inhalers (MDIs) at the CPHI/ICSE Europe tradeshow to be held on October 4-6, in Barcelona.
Our patented eDose Counter for MDIs is designed to be easy-to-use and reliable, and contributes to patient compliance.
Our unique sensing technology offers direct detection of the spray which eliminates risks of miscounting.
The sensing technology is versatile and compatible with any metering valve design. In addition, our eDose Counter for MDIs includes inhaler priming and medication reminders-to-use and end-of-product-life warnings (flashing digits) while remaining cost-effective.
For further details on eDose Counter for MDIs, please visit our booth #2M18, Hall 2 (Innopack area) and liaise with Chris Baron, our Associate Director Business Development: chris.baron@aptar.com, or visit our website at aptar.com/pharma.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
